BibTex RIS Kaynak Göster

The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia

Yıl 2010, Cilt: 1 Sayı: 1, 68 - 70, 01.03.2010
https://doi.org/10.5799/ahinjs.01.2010.01.0014

Öz

Kaynakça

  • Laurenti L, Tarnani M, De Padua L, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in pa- tients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hema- tol 2008;87:891-8.
  • Catovsky D, Richards S, Matutes E, et al. Assessment of flu- darabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:197-8.
  • Lin TS. What is the optimal initial treatment for chron- ic lymphocytic leukemia? Oncology (Williston Park) 2007;21:1641-9
  • Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunother- apy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:479- 80.
  • Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral flu- darabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008;26:247-51.
  • Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral flu- darabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90-3.
  • Cazin B, Divine M, Leprêtre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclo- phosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008;143:54-9. 2008;143:54-9.

The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia

Yıl 2010, Cilt: 1 Sayı: 1, 68 - 70, 01.03.2010
https://doi.org/10.5799/ahinjs.01.2010.01.0014

Öz

The aim of this study was to evaluate the efficiency, as well as the hematologic and non-he

Kaynakça

  • Laurenti L, Tarnani M, De Padua L, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in pa- tients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hema- tol 2008;87:891-8.
  • Catovsky D, Richards S, Matutes E, et al. Assessment of flu- darabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:197-8.
  • Lin TS. What is the optimal initial treatment for chron- ic lymphocytic leukemia? Oncology (Williston Park) 2007;21:1641-9
  • Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunother- apy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:479- 80.
  • Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral flu- darabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia. Hematol Oncol 2008;26:247-51.
  • Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral flu- darabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90-3.
  • Cazin B, Divine M, Leprêtre S, et al. High efficacy with five days schedule of oral fludarabine phosphate and cyclo- phosphamide in patients with previously untreated chronic lymphocytic leukaemia. Br J Haematol 2008;143:54-9. 2008;143:54-9.
Toplam 7 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Editöre Mektup
Yazarlar

Osman Yokuş Bu kişi benim

Özlem Şahin Balcık Bu kişi benim

Murat Albayrak Bu kişi benim

Yayımlanma Tarihi 1 Mart 2010
Yayımlandığı Sayı Yıl 2010 Cilt: 1 Sayı: 1

Kaynak Göster

APA Yokuş, O., Balcık, Ö. Ş., & Albayrak, M. (2010). The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. Journal of Clinical and Experimental Investigations, 1(1), 68-70. https://doi.org/10.5799/ahinjs.01.2010.01.0014
AMA Yokuş O, Balcık ÖŞ, Albayrak M. The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. J Clin Exp Invest. Mart 2010;1(1):68-70. doi:10.5799/ahinjs.01.2010.01.0014
Chicago Yokuş, Osman, Özlem Şahin Balcık, ve Murat Albayrak. “The Efficiency and Side-Effects of Low-Dose Fludarabine-Cyclophosphamide in the Treatment of Chronic Lymphocytic Leukemia”. Journal of Clinical and Experimental Investigations 1, sy. 1 (Mart 2010): 68-70. https://doi.org/10.5799/ahinjs.01.2010.01.0014.
EndNote Yokuş O, Balcık ÖŞ, Albayrak M (01 Mart 2010) The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. Journal of Clinical and Experimental Investigations 1 1 68–70.
IEEE O. Yokuş, Ö. Ş. Balcık, ve M. Albayrak, “The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia”, J Clin Exp Invest, c. 1, sy. 1, ss. 68–70, 2010, doi: 10.5799/ahinjs.01.2010.01.0014.
ISNAD Yokuş, Osman vd. “The Efficiency and Side-Effects of Low-Dose Fludarabine-Cyclophosphamide in the Treatment of Chronic Lymphocytic Leukemia”. Journal of Clinical and Experimental Investigations 1/1 (Mart 2010), 68-70. https://doi.org/10.5799/ahinjs.01.2010.01.0014.
JAMA Yokuş O, Balcık ÖŞ, Albayrak M. The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. J Clin Exp Invest. 2010;1:68–70.
MLA Yokuş, Osman vd. “The Efficiency and Side-Effects of Low-Dose Fludarabine-Cyclophosphamide in the Treatment of Chronic Lymphocytic Leukemia”. Journal of Clinical and Experimental Investigations, c. 1, sy. 1, 2010, ss. 68-70, doi:10.5799/ahinjs.01.2010.01.0014.
Vancouver Yokuş O, Balcık ÖŞ, Albayrak M. The efficiency and side-effects of low-dose Fludarabine-Cyclophosphamide in the treatment of chronic lymphocytic leukemia. J Clin Exp Invest. 2010;1(1):68-70.